Holen Sie sich die Stockscreener-App
53.35
1.68%
-0.91
Schlusskurs vom Vortag:
$54.26
Offen:
$53.69
24-Stunden-Volumen:
952.94K
Relative Volume:
3.65
Marktkapitalisierung:
$1.12B
Einnahmen:
$486.82M
Nettoeinkommen (Verlust:
$18.78M
KGV:
-111.15
EPS:
-0.48
Netto-Cashflow:
$100.45M
1W Leistung:
-5.73%
1M Leistung:
-3.18%
6M Leistung:
-10.17%
1J Leistung:
+1.95%
1-Tages-Spanne:
$53.00
$54.56
1-Wochen-Bereich:
$52.50
$57.33
52-Wochen-Spanne:
$52.00
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
53.35 | 1.12B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
Wellington Management Group LLP Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
State Street Corp Acquires 58,698 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Insider Sell: Stephen Carey Sells 7,500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus.com
Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock By Investing.com - Investing.com South Africa
Ani Pharmaceuticals CFO sells $418,425 in stock - Investing.com
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares - Simply Wall St
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Barclays PLC - MarketBeat
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock - Investing.com
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock By Investing.com - Investing.com Australia
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.03 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Key Pharmaceutical Suspension Market Trend 2024-2033: ANI Pharmaceuticals Launches Kionex Suspension - EIN News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decrease in Short Interest - MarketBeat
Insider Sell: Krista Davis Sells 1,000 Shares of ANI Pharmaceuti - GuruFocus.com
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of ANI Pharmaceuticals (ANIP) with Outperform Recommendation - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Leerink Partners - MarketBeat
Where ANI Pharmaceuticals Stands With Analysts - Benzinga
Charles Schwab Investment Management Inc. Buys 8,869 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Hotchkis & Wiley Capital Management LLC Buys Shares of 52,080 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Intrauterine Devices Market Report Forecasts and Company - GlobeNewswire
Intrauterine Devices Market Report Forecasts and Company Analysis 2024-2032, Profiles of AbbVie, Bayer, Teva Pharmaceuticals, ANI Pharmaceuticals, Mylan, CooperSurgical. and DKT International - Yahoo Finance
Ani Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Martingale Asset Management L P Purchases 13,719 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Bank of Montreal Can Makes New $13.04 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Down 2.9%Here's Why - MarketBeat
Intech Investment Management LLC Acquires New Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Ani Pharmaceuticals Insider Sold Shares Worth $1,941,442, According to a Recent SEC Filing - Marketscreener.com
Ani Pharmaceuticals CEO Nikhil Lalwani sells $1.94 million in stock - Investing.com India
Ani Pharmaceuticals CEO Nikhil Lalwani sells $1.94 million in stock By Investing.com - Investing.com Australia
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Holdings Decreased by Rubric Capital Management LP - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Eagle Asset Management Inc. Purchases New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals CEO to Present at Piper Sandler Healthcare Conference - StockTitan
Pacer Advisors Inc. Acquires 565,910 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Thompson Siegel & Walmsley LLC Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Global Alpha Capital Management Ltd. - MarketBeat
Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St
ANI Pharmaceuticals Q3 2024 Earnings Preview - MSN
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update - MarketBeat
Mizuho Markets Americas LLC Makes New $11.67 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Athlete′s Foot Drugs Market: Global Trends, Demand, - openPR
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance
Rubric Capital Management LP Adjusts Stake in ANI Pharmaceuticals Inc - GuruFocus.com
ANI Pharmaceuticals Inc (ANIP) Stock Price Up 2.37% on Nov 13 - GuruFocus.com
Lisanti Capital Growth LLC Has $890,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals maintains Buy rating, target at $94 By Investing.com - Investing.com UK
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):